Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × incomplete Freund's adjuvant × Other hematologic neoplasm × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡